Athenex, Inc. (ATNX)

NASDAQ: ATNX · IEX Real-Time Price · USD
1.00
-0.06 (-5.66%)
At close: Jan 21, 2022 4:00 PM
1.02
0.02 (2.00%)
After-hours:Jan 21, 2022 6:16 PM EST
Market Cap109.32M
Revenue (ttm)117.05M
Net Income (ttm)-144.87M
Shares Out109.32M
EPS (ttm)-1.45
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume897,335
Open1.05
Previous Close1.06
Day's Range1.00 - 1.06
52-Week Range1.00 - 15.00
Beta0.57
AnalystsBuy
Price Target7.50 (+650.0%)
Earnings Daten/a

About ATNX

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral Paclitaxel, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignancies and gastric cancer; and Oral Irinotecan and Encequidar, a potent anticancer d...

IndustryBiotechnology
IPO DateJun 14, 2017
CEOJohnson Lau
Employees593
Stock ExchangeNASDAQ
Ticker SymbolATNX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for Athenex stock is "Buy." The 12-month stock price forecast is 7.50, which is an increase of 650.00% from the latest price.

Price Target
$7.50
(650.00% upside)
Analyst Consensus: Buy

News

Athenex Announces Agreement with ImmunityBio Regarding Dunkirk Manufacturing Facility

BUFFALO, N.Y., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 week ago - GlobeNewsWire

SHAREHOLDER ALERT: Robbins LLP is Investigating Athenex, Inc. (ATNX) for Shareholders

SAN DIEGO, Calif. & BUFFALO, N.Y.--(BUSINESS WIRE)---- $ATNX #breastcancer--Athenex, Inc. (ATNX) Misstated the Efficacy of its Lead Drug Candidate and the Likelihood the FDA Would Approve its New Drug A...

3 weeks ago - Business Wire

Athenex to Host a KOL Webinar Today on CAR-NKT Cell Approach to Cancer and Latest Data at the 63rd ASH Annual Meeting

The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform

1 month ago - GlobeNewsWire

Athenex Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar fo...

BUFFALO, N.Y., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 month ago - GlobeNewsWire

Athenex To Present Subgroup Analysis Of Oral Paclitaxel-Encequidar Combo Data From Breast Cancer Trial

Athenex Inc's (NASDAQ: ATNX) abstract for subgroup analysis of its Phase 3 study of oral paclitaxel and encequidar (Oral Paclitaxel) for metastatic breast cancer has been accepted for poster presentatio...

2 months ago - Benzinga

Are Options Traders Betting on a Big Move in Athenex (ATNX) Stock?

Investors need to pay close attention to Athenex (ATNX) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

Athenex to Present at the Evercore ISI 4th Annual HealthCONx Conference

BUFFALO, N.Y., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

2 months ago - GlobeNewsWire

Athenex Announces Exclusive License Agreement with National Cancer Institute to Utilize T Cell Receptors Targeting Mu...

Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs to target solid tumors Athenex plans to expand the allogeneic NKT cell R&D pipeline with these new licensed TCRs...

2 months ago - GlobeNewsWire

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and 66.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Athenex Presents Interim Data from ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory ...

Results from five patients showed best responses of 2 partial responses (PR), 1 complete response with incomplete hematological recovery (CRi) and 1 complete response (CR).

2 months ago - GlobeNewsWire

Athenex (ATNX) Sees Hammer Chart Pattern: Time to Buy?

Athenex (ATNX) has been struggling lately, but the selling pressure may be coming to an end soon.

2 months ago - Zacks Investment Research

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 4, 2021

BUFFALO, N.Y., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

3 months ago - GlobeNewsWire

Athenex to Provide Corporate and Financial Update for the Third Quarter 2021, on November 5, 2021

BUFFALO, N.Y., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

3 months ago - GlobeNewsWire

Athenex and the Center for Cell and Gene Therapy Announce Allowance of Our First U.S. Patent Claims Around CAR-NKT Ce...

Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR)

3 months ago - GlobeNewsWire

After Plunging 25.6% in 4 Weeks, Here's Why the Trend Might Reverse for Athenex (ATNX)

Athenex (ATNX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates cou...

3 months ago - Zacks Investment Research

Athenex Provides Update from FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar in Metastatic Breast Cancer

BUFFALO, N.Y., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

3 months ago - GlobeNewsWire

5 Penny Stocks To Buy According To Insiders In September

Insiders are buying shares of these penny stocks this months; are you? The post 5 Penny Stocks To Buy According To Insiders In September appeared first on Penny Stocks to Buy, Picks, News and Informatio...

Other symbols:HOFVNGLNMTRTUEM
4 months ago - PennyStocks

Athenex Shares Are Trading Higher On Positive Oral Paclitaxel Data From Solid Tumor Trial

Athenex Inc (NASDAQ: ATNX) announced data presentation from a Phase 1 study evaluating encequidar (Oral Paclitaxel) in combination with Merck Co Inc's (NYSE: MRK) Keytruda (pembrolizumab) in advanced so...

4 months ago - Benzinga

Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 Study at ESMO 2021

Safety Data Help Establish Part B Dose Expansion and Phase 2 Dose; Data showed encouraging anti-tumor activity (4 PR out of 8 evaluable patients) in NSCLC patients who failed prior PD1/PDL1 therapies Sa...

4 months ago - GlobeNewsWire

Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life Sciences & Med Tech Summit

BUFFALO, N.Y., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

4 months ago - GlobeNewsWire

Athenex (ATNX) Reports Q2 Loss, Misses Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 19.51% and -0.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Athenex Provides Second Quarter 2021 Corporate and Financial Update

Updated investors on FDA Type A Meeting for oral paclitaxel

5 months ago - GlobeNewsWire

Athenex Announces Additional Licensing Agreements for Tirbanibulin

Athenex expands its international commercial partnerships for tirbanibulin in Australia, New Zealand and Canada Athenex expands its international commercial partnerships for tirbanibulin in Australia, N...

5 months ago - GlobeNewsWire

Athenex to Provide Corporate and Financial Update for the Second Quarter 2021 on August 5, 2021

BUFFALO, N.Y., July 22, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

6 months ago - GlobeNewsWire

Athenex (ATNX) Skin Treatment Klisyri Gets Approval in Europe

Athenex (ATNX) announces approval for its skin treatment drug, Klisyri, in Europe. The company's partner Almirall is set to handle the launch of the drug in the region.

6 months ago - Zacks Investment Research